Independent register of U.S. FDA drug recalls · updated Oct 12, 2026
RxRecalls Get alerts

Sterility & contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections.

6,317 FDA drug recalls with this cause, newest first.

This is the single biggest cause in the register by a wide margin. It covers products that had to be sterile - injectables, eye drops, certain ointments - but could not be verified sterile, or were found contaminated during testing. Most of these recalls come from compounding pharmacies and outsourcing facilities after an FDA inspection finds gaps in how sterile products were made. Sterility failures are treated seriously because the products involved have the least room for error, going straight into the bloodstream or the eye.

Class II · Moderate risk

Triamcinolone Acetonide 40 mg/mL

Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

Terminated Sterility / contamination Isomeric Pharmacy Solution, LLC D-0683-2017
Class II · Moderate risk

Metronidazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-001-24 D-0616-2017
Class II · Moderate risk

Levofloxacin Injection in 5% Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-048-24 D-0615-2017
Class II · Moderate risk

Fluconazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-003-06 D-0614-2017
Class II · Moderate risk

Ciprofloxacin in Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-009-24 D-0613-2017
Class II · Moderate risk

Dorama-Neo

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-020-01 D-0856-2017
Class II · Moderate risk

Sato Clear

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-044-01 D-0855-2017
Class II · Moderate risk

Optic Splash

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-501-01 D-0854-2017